VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$9.00Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $553,907,456.00
EPSttm : -3.5
Verastem, Inc.
$9.00
4.53%$0.39Float Short %
29.46
Margin Of Safety %
Put/Call OI Ratio
0.15
EPS Next Q Diff
0.02
EPS Last/This Y
1.23
EPS This/Next Y
0.49
Price
8.98
Target Price
15.5
Analyst Recom
1
Performance Q
87.11
Relative Volume
0.73
Beta
0.89
Ticker: VSTM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | VSTM | 10.23 | 0.18 | 0.48 | 25860 |
| 2025-09-09 | VSTM | 9.93 | 0.20 | 0.04 | 27508 |
| 2025-09-10 | VSTM | 9.84 | 0.20 | 1.24 | 27514 |
| 2025-09-11 | VSTM | 9.34 | 0.22 | 0.38 | 27828 |
| 2025-09-12 | VSTM | 9.76 | 0.22 | 0.28 | 27935 |
| 2025-09-15 | VSTM | 9.82 | 0.22 | 0.22 | 27958 |
| 2025-09-16 | VSTM | 9.12 | 0.23 | 0.96 | 27967 |
| 2025-09-17 | VSTM | 9.44 | 0.23304143249248 | 1.5643564356436 | 28302 |
| 2025-09-18 | VSTM | 9.53 | 0.25 | 0.77 | 28628 |
| 2025-09-22 | VSTM | 9.13 | 0.10 | 0.01 | 11489 |
| 2025-09-23 | VSTM | 9.19 | 0.10 | 0.01 | 11899 |
| 2025-09-24 | VSTM | 8.6 | 0.09 | 1.17 | 11994 |
| 2025-09-25 | VSTM | 8.62 | 0.12 | 0.25 | 12553 |
| 2025-09-26 | VSTM | 8.88 | 0.12 | 1.79 | 12601 |
| 2025-09-29 | VSTM | 8.63 | 0.14 | 5.58 | 12844 |
| 2025-09-30 | VSTM | 8.82 | 0.14 | 0.78 | 12922 |
| 2025-10-01 | VSTM | 8.8 | 0.14 | 2.18 | 13020 |
| 2025-10-02 | VSTM | 9 | 0.15 | 0.66 | 13044 |
| 2025-10-03 | VSTM | 8.68 | 0.15 | 0.19 | 13076 |
| 2025-10-06 | VSTM | 8.61 | 0.15 | 1.53 | 13169 |
| 2025-10-07 | VSTM | 9 | 0.15 | 2.51 | 13187 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | VSTM | 10.23 | 30.3 | - | -2.44 |
| 2025-09-09 | VSTM | 9.93 | 30.3 | - | -2.44 |
| 2025-09-10 | VSTM | 9.88 | 30.3 | - | -2.44 |
| 2025-09-11 | VSTM | 9.35 | 30.3 | - | -2.44 |
| 2025-09-12 | VSTM | 9.72 | 30.3 | - | -2.44 |
| 2025-09-15 | VSTM | 9.82 | 30.3 | - | -2.44 |
| 2025-09-16 | VSTM | 9.13 | 30.3 | - | -2.44 |
| 2025-09-17 | VSTM | 9.44 | 30.3 | - | -2.44 |
| 2025-09-18 | VSTM | 9.53 | 30.3 | - | -2.44 |
| 2025-09-19 | VSTM | 9.04 | 30.3 | - | -2.44 |
| 2025-09-22 | VSTM | 9.13 | 30.3 | - | -2.44 |
| 2025-09-23 | VSTM | 9.19 | 30.3 | - | -2.44 |
| 2025-09-24 | VSTM | 8.59 | 30.3 | - | -2.44 |
| 2025-09-25 | VSTM | 8.61 | 30.3 | - | -2.44 |
| 2025-09-26 | VSTM | 8.89 | 30.3 | - | -2.44 |
| 2025-09-29 | VSTM | 8.63 | 30.3 | - | -2.44 |
| 2025-09-30 | VSTM | 8.83 | 30.3 | - | -2.44 |
| 2025-10-01 | VSTM | 8.81 | 30.3 | - | -2.44 |
| 2025-10-02 | VSTM | 8.99 | 30.3 | - | -2.44 |
| 2025-10-03 | VSTM | 8.70 | 30.3 | - | -2.44 |
| 2025-10-06 | VSTM | 8.62 | 30.3 | - | -2.44 |
| 2025-10-07 | VSTM | 8.98 | 30.3 | - | -2.44 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-09 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-10 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-11 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-12 | VSTM | -1.89 | 17.35 | 27.96 |
| 2025-09-15 | VSTM | -2.12 | 17.42 | 27.96 |
| 2025-09-16 | VSTM | -2.12 | 17.42 | 27.96 |
| 2025-09-17 | VSTM | -2.12 | 17.42 | 27.96 |
| 2025-09-18 | VSTM | -2.12 | 17.42 | 27.96 |
| 2025-09-19 | VSTM | -2.14 | 17.42 | 27.96 |
| 2025-09-22 | VSTM | -2.12 | 17.42 | 27.96 |
| 2025-09-23 | VSTM | -2.12 | 17.42 | 27.96 |
| 2025-09-24 | VSTM | -2.12 | 17.42 | 27.96 |
| 2025-09-25 | VSTM | -2.12 | 17.42 | 29.46 |
| 2025-09-26 | VSTM | -2.12 | 17.42 | 29.46 |
| 2025-09-29 | VSTM | -2.12 | 17.42 | 29.46 |
| 2025-09-30 | VSTM | -2.12 | 17.42 | 29.46 |
| 2025-10-01 | VSTM | -2.12 | 17.42 | 29.46 |
| 2025-10-02 | VSTM | -2.12 | 17.42 | 29.46 |
| 2025-10-03 | VSTM | -2.12 | 17.42 | 29.46 |
| 2025-10-06 | VSTM | -2.12 | 1.18 | 29.46 |
| 2025-10-07 | VSTM | -2.12 | 1.18 | 29.46 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.63
Avg. EPS Est. Current Quarter
-0.61
Avg. EPS Est. Next Quarter
-0.61
Insider Transactions
-2.12
Institutional Transactions
1.18
Beta
0.89
Average Sales Estimate Current Quarter
5
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
10
Growth Score
33
Sentiment Score
48
Actual DrawDown %
84.8
Max Drawdown 5-Year %
-96.2
Target Price
15.5
P/E
Forward P/E
PEG
P/S
258.83
P/B
15.36
P/Free Cash Flow
EPS
-3.51
Average EPS Est. Cur. Y
-2.44
EPS Next Y. (Est.)
-1.94
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7793.82
Relative Volume
0.73
Return on Equity vs Sector %
-487.1
Return on Equity vs Industry %
-473.4
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.16
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading